Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,384.39 121.83 0.75%
S&P 500 1,857.78 14.80 0.80%
NASDAQ 4,071.34 37.18 0.92%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Drug Designation, Patents, Milestone Payment, Quarterly Result, and Medical Study - Research Report on The Medicines Company,



 Drug Designation, Patents, Milestone Payment, Quarterly Result, and Medical
Study - Research Report on The Medicines Company, VIVUS, Isis, HeartWare, and
                                    Masimo

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 20, 2013

NEW YORK, November 20, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting The
Medicines Company (NASDAQ: MDCO), VIVUS Inc. (NASDAQ: VVUS), Isis
Pharmaceuticals, Inc. (NASDAQ: ISIS), HeartWare International Inc. (NASDAQ:
HTWR), and Masimo Corporation (NASDAQ: MASI). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

The Medicines Company Research Report

On November 12, 2013, The Medicines Company announced that the US Food and
Drug Administration (FDA) has designated oritavancin, the Company's
investigational Antibiotic, as a Qualified Infectious Disease Product (QIDP).
According to the Company, the QIDP designation provides oritavancin priority
review by the FDA, eligibility for FDA's "fast track" status, and an
additional five years of exclusivity upon approval of the product for the
treatment of acute bacterial skin and skin structure infections (ABSSSI).
Further, The Medicines Company stated that the QIDP designation was granted on
the basis of the Generating Antibiotic Incentives Now (GAIN) Act, included in
the FDA Safety and Innovation Act (FDASIA) that was signed into law in 2012.
The Company reported that it intends to submit a New Drug Application to the
FDA in Q4 2013 for the use of oritavancin in ABSSSI caused by susceptible
gram-positive bacteria, including methicillin-resistant Staphylococcus aureus
(MRSA). The Full Research Report on The Medicines Company - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5a84_MDCO

--

VIVUS Inc. Research Report

On November 13, 2013, VIVUS Inc. (VIVUS) announced that the US Patent and
Trademark Office has issued US Patent Nos. 8,580,298, covering compositions of
Qsymia, and 8,580,299, covering methods for effecting weight loss using
Qsymia. Seth H. Z. Fischer, CEO of VIVUS, commented, "The issuance of these
new Qsymia patents is an important achievement for VIVUS." Fischer added,
"Extension of our patent coverage by an additional nine years adds significant
value to the Qsymia franchise. The new patents provide us with a greater
opportunity to promote Qsymia as a highly effective therapy of choice for
obese patients and for overweight patients with one or more comorbidities."
The Full Research Report on VIVUS Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.AnalystsCorner.com/r/full_research_report/8ae9_VVUS

--

Isis Pharmaceuticals, Inc. Research Report

On November 15, 2013, Isis Pharmaceuticals, Inc. (Isis) announced that it has
earned a $5 million milestone payment from GlaxoSmithKline in relation to the
designation of ISIS-GSK4Rx as a development candidate. Isis reported that the
ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular
disease. B. Lynne Parshall, Chief Operating Officer at Isis, said, "Our
collaboration with GlaxoSmithKline has been very productive resulting in three
novel antisense drugs in our pipeline." Parshall continued, "We look forward
to advancing ISIS-GSK4Rx into the clinic and providing more information on the
target and disease opportunity, which we are very excited about." The Full
Research Report on Isis Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.AnalystsCorner.com/r/full_research_report/fcfc_ISIS

--

HeartWare International Inc. Research Report

On November 7, 2013, HeartWare International Inc. (HeartWare) released its Q3
2013 results. HeartWare registered net revenues of $54.8 million in Q3 2013,
up 139.7% YoY. The Company posted net loss of $11.4 million in Q3 2013,
compared to net loss of $25.0 million in Q3 2012. HeartWare reported diluted
loss per share of $0.69 in Q3 2013, compared to diluted loss per share of
$1.75 in Q3 2012. Doug Godshall, President and CEO of HeartWare, stated, "Our
results for the third quarter reflect continued positive trends in the
commercial launch of the HeartWare System in the US, following approval from
Food and Drug Administration (FDA) late last year, as well as continued strong
support from our international customers." The Full Research Report on
HeartWare International Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/0461_HTWR

--

Masimo Corporation Research Report

On November 5, 2013, Masimo Corporation (Masimo) announced a new study in the
Journal of Critical Care which shows that the Company's noninvasive PVI can be
helpful for clinicians to accurately assess fluid responsiveness in
mechanically ventilated patients in the early phase of septic shock in the
emergency room. Steve Barker, M.D., Ph.D., Interim Chief Medical Officer of
Masimo, explained, "This study demonstrates the practical and cost-effective
advantage of PVI, particularly for physicians for whom time and ease of use
are of the essence. The findings also add to the growing body of evidence that
shows the efficacy of PVI across a wide range of patient populations." The
Full Research Report on Masimo Corporation - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.AnalystsCorner.com/r/full_research_report/6e22_MASI

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement